Alecensa 150 MG capsule UU 240S
Ended Awarded Last action
- Contract number
- SPE2DR26FCRQ8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $39,136
Award facts
- Contract value 100% obligated
- $39,135.57 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $39,135.57 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. for Alecensa 150 mg capsules (240 count) on December 18, 2025, with completion targeted for January 12, 2026. The order was issued without a set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, serves as a critical supplier within the federal pharmaceutical supply chain, specializing in distributing comprehensive ranges of pharmaceutical products and medical consumables to the Department of Defense.
This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, awarded November 13, 2025, with a $499.999 billion ceiling and completion date of December 31, 2036. The parent contract positions DMS Pharmaceutical Group as one of multiple regional prime vendor contractors within the broader $30.3 billion PPV-G GEN V acquisition strategy, authorizing the issuance of firm fixed-price delivery orders for branded and generic prescription drugs, biologics, and medical consumables to support Department of Defense healthcare operations globally. Alecensa, an oncology treatment, represents a specialized pharmaceutical product within the vendor's extensive portfolio of cancer medications supplied to military healthcare facilities.
Quick answers
Who was awarded contract SPE2DR26FCRQ8?
SPE2DR26FCRQ8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 18, 2025.
How much is contract SPE2DR26FCRQ8 worth?
The government has obligated $39,136 on SPE2DR26FCRQ8.
Is contract SPE2DR26FCRQ8 an order under another contract?
Yes. SPE2DR26FCRQ8 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRQ8 competed?
The extent of competition for SPE2DR26FCRQ8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award